Searchable abstracts of presentations at key conferences in endocrinology

ea0031p114 | Clinical practice/governance and case reports | SFEBES2013

Audit of the management of primary hyperparathyroidism at Watford general hospital

Allum Matthew , Clements Michael

Introduction: Primary hyperparathyroidism (PHPT) can only be cured by parathyroidectomy (PTX) but mild and asymptomatic cases can often be managed conservatively. We carried out a retrospective audit of patients attending the Endocrine clinic at Watford to determine how our practice compared with the different guidelines for surgical referral published in the USA and the UK.Method: A search was carried out of clinic letters from Jan 2010 to Oct 2011. Add...

ea0021p289 | Pituitary | SFEBES2009

A fall in serum prolactin level after a 2-h rest predicts a normal MRI in patients using dopamine antagonist treatment

Whyte Martin , Allum Matthew , Pramodh Sesha , Aylwin Simon

Introduction: Hyperprolactinaemia associated with antipsychotic drug use is a commonly encountered clinical problem, yet no decision-making tools exist to guide whether to scan the pituitary gland.Methods: A 10-year data series was reviewed of 246 patients who were evaluated for prolactin excess with a cannulated prolactin study. All patients had a prolactin drawn immediately following the insertion of a forearm cannula (P1) and a second sampl...

ea0077p70 | Metabolism, Obesity and Diabetes | SFEBES2021

Real-world metabolic outcomes of semaglutide use in patients with type 2 diabetes: a retrospective study from a single centre in the United Arab Emirates

Allum Matthew , Buckley Adam , Lessan Nader , Mohammed Nagi , Suliman Mohamed , Suliman Sara , Elsheikh Mohgah

Background: The Glucagon-like peptide-1 receptor agonist (GLP1RA) semaglutide has shown improvements in glycaemia and other metabolic parameters for patients with type 2 diabetes (T2D) in clinical trials. Published real-world data are sparse and there are none from the Middle East where semaglutide became available in 2020.Method and Results: We retrospectively gathered data for 289 patients (median age 50 years (IQR 42-57), 36% female, 87% Emirati and 8...

ea0099p455 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Effect of prior GLP-1 RA treatment on clinical outcomes in patients with type 2 diabetes initiating treatment with tirzepatide

Suliman Mohammed , Buckley Adam , Allum Matthew , Lessan Nader , Mohammed Nagi , le Roux Carel , Suliman Sara

Background: Tirzepatide is a GLP-1/GIP co-agonist treatment for type 2 diabetes. Participants in the SURPASS trials were GLP-1RA naïve, but in clinical practice many patients are switched from other GLP-1RAs.Aims: To explore effects of prior GLP-1RA treatment on tirzepatide therapy outcomes.Methods: Review of clinical data from an outpatient Diabetes centre. Adults with 6 months follow-up post tirzepatide initiation were inclu...

ea0099ep666 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Monogenic obesity prevalence and response to bariatric surgery in a cohort of Emirati patients

Ashraf Tanveer , AlKaf Budour , Radha Saradalekshmi , Fojas Esphie , Baqer Amal , Khaled Rayan , Suliman Sara , Allum Matthew , Lessan Nader

Introduction: We have previously shown good short-term but variable long-term weight loss outcomes of bariatric surgery (BS) in a cohort of obese patients with MC4R deficiency. This study aims to elucidate the epidemiological landscape of Monogenic Obesity (MO) and quantify bariatric surgery’s effectiveness in weight reduction among Emirati patients with severe obesity. Methods: We selected a group of patients with extreme obesity (>50 kg/m...